aTyr Pharma News

Name: aTyr Pharma News
Address: 3545 John Hopkins Court, Suite #250, San Diego, CA, 92121, US
Telephone: (858) 731-8389

Home
United States
San Diego, CA
aTyr Pharma News

aTyr Pharma is a biotherapeutics company engaged in the discovery and clinical development

06/01/2026

June is Scleroderma Awareness Month, where we work to advocate for the more than 2 million people worldwide living with this autoimmune disease. At aTyr, we are working to develop efzofitimod as a potential new treatment for those living with a form of scleroderma that impacts the lungs, called systemic sclerosis-related interstitial lung disease, or SSc-ILD. Learn more at www.atyrpharma.com.

04/30/2026

In honor of Sarcoidosis Awareness Month, members of the aTyr team joined the Take a Breath for Sarcoidosis Virtual Run/Walk hosted by the Life & Breath Foundation for Sarcoidosis. Collectively, this past weekend we walked over 250 miles in support of the more than 200,000 people living with sarcoidosis in the U.S.

On this National Sarcoidosis Awareness Day, learn more about what the Life and Breath Foundation for Sarcoidosis is doing to help sarcoidosis patients live well at www.lifeandbreath.org/.

04/13/2026

Today is World Sarcoidosis Day, which is an important opportunity to spread awareness and understanding of this chronic, immune-driven inflammatory disease that affects more than 1 million individuals worldwide. We would like to acknowledge the community of patients, providers, caregivers and partners who dedicate their time and effort to working to improve the lives of those living with sarcoidosis. Together we can make a difference.

04/01/2026

April is Sarcoidosis Awareness Month. During this time, we invite you join us as we advocate and raise awareness for the more than one million individuals living with sarcoidosis worldwide. We are proud to support the sarcoidosis community by working to develop efzofitimod as a potential new treatment for those living with pulmonary sarcoidosis, major form of interstitial lung disease where a significant proportion of patients develop chronic or progressive disease with debilitating symptoms despite current treatment options. Learn more at www.atyrpharma.com.

09/15/2025

Today we announced topline results from our Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. While the study did not meet its primary endpoint in change from baseline in mean daily oral corticosteroid dose at week 48, clinical benefit for efzofitimod was observed across multiple study parameters, including the King’s Sarcoidosis Questionnaire-Lung score. Additionally, efzofitimod was generally well-tolerated, consistent with a previously observed safety profile in all trials conducted to date.

Based on these findings, we plan to engage with the U.S. Food and Drug Administration to review the results and determine the path forward for efzofitimod in pulmonary sarcoidosis.

Read more here: https://bit.ly/3IqCOu1

09/10/2025

Today is the fifth annual ILD Day! Join us in taking some time to acknowledge this important day that is dedicated to generating awareness of interstitial lung disease (ILD), a group of more than 200 rare, immune-mediated disorders that can cause progressive fibrosis, or scarring, of the lungs. aTyr is proud to support the ILD community by working to develop efzofitimod as a potential new treatment for those living with forms of ILD, including pulmonary sarcoidosis and SSc-ILD.

Learn more about ILD Day here: http://bit.ly/45MRP2g

07/16/2025

Do you have pulmonary sarcoidosis and want to talk about your symptoms? You may be eligible to join an online research study to evaluate a questionnaire that measures lung health symptoms and is used in clinical trials for pulmonary sarcoidosis.

Contact the study team at [email protected] for more information or visit https://bit.ly/440rkWk to see if you may qualify.

06/29/2025

Today is World Awareness Day, where we take the time to acknowledge and advocate for everyone living with this rare disease. At aTyr, we are working to develop efzofitimod as a potential new treatment for those living with a form of interstitial lung disease (ILD) related to systemic sclerosis (SSc), called . Learn more at www.atyrpharma.com.

06/01/2025

June is Scleroderma Awareness Month. This is an important time to advocate and generate awareness for the more than 2 million people worldwide that are estimated to be living with this autoimmune disease. At aTyr, we are working to develop efzofitimod as a potential new treatment for those living with a form of interstitial lung disease (ILD) related to systemic sclerosis (SSc), called SSc-ILD. Learn more at www.atyrpharma.com.

04/13/2025

On this World Sarcoidosis Day, it is important to raise awareness of this rare disease for which there is no known cause and no cure. aTyr stands with the sarcoidosis community, and together we will work to improve the lives of the more than one million individuals living with sarcoidosis worldwide.

Address

3545 John Hopkins Court, Suite #250
San Diego, CA
92121

Telephone

(858) 731-8389

Website

http://www.atyrpharma.com/

Alerts

Be the first to know and let us send you an email when aTyr Pharma News posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

SD Prototypes Manufacturing Solutions, Inc.
8616 Commerce Avenue

Want your business to be the top-listed Engineering Company in San Diego?